Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
AGENCY
HHS-NIH11
PROGRAM
Discretionary
AMOUNT
—
CLOSES
Nov 19, 2026
Description
Eligibility
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Others (see text field entitled "Additional Information on Eligibility" for clarification); Special district governments; Public and State controlled institutions of higher education; For profit organizations other than small businesses; Private institutions of higher education; City or township governments; State governments; Small businesses; Native American tribal organizations (other than Federally recognized tribal governments); Native American tribal governments (Federally recognized); County governments; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Contact
Additional details
- Funding instrument
- Cooperative Agreement
- Cost sharing required
- No
- Archived
- Dec 25, 2026
Opportunity number: PAR-25-226
Search this number on Grants.gov for the official listing.